Wide disparities in access to latest rheumatoid arthritis drugs across Europe

March 6, 2013, British Medical Journal

The cost of one year's treatment of rheumatoid arthritis with new generation drugs is more than the per capita gross domestic product of 26 European countries, reveals research published online in the Annals of the Rheumatic Diseases.

This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers.

DMARDs are extremely effective for the treatment of , and the European League Against (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt progress of the disease. But they are expensive.

The authors therefore surveyed key experts in 49 countries during 2011 about the availability, affordability and of both synthetic DMARDs, such as and leflunomide, and biological DMARDs, such as and .

In all, 46 countries took part in the survey, which included those in Eastern Europe, Scandinavia, and Western Europe, as well as Turkey and Uzbekistan.

The responses revealed wide in access to DMARDs. Six countries did not reimburse use of any of the five synthetic DMARDs included in the survey, and 10 countries did not pay for any biological DMARDs.

The cost of one year's treatment with a synthetic DMARD did not exceed any country's per capita GDP). But the cost of one year's treatment with a biological DMARD was higher than the per capita GDP of 26 countries, by as much as 11 times, the findings indicated.

That means that almost 40% of the population of Europe - equivalent to 320 million people - would have severely restricted access to biological DMARDs, say the authors.

Access was especially poor in countries in Central and Eastern Europe and those least well off, economically and socially, the findings showed.

The number of days a person on an average income would need to work to pay fhe full drug price of 30 days' treatment with a biological DMARD ranged from 12 days in Luxembourg to 190 in Romania.

Although it's not possible to draw definitive conclusions on the impact on health of restricted access, higher drugs prices were associated with increased disease activity and poorer physical functioning.

"Assuming needs for treatment with DMARDs are similar across countries, differences in access to medical treatment are unfair and raise alarming issues of inequity," write the authors.

Wealthy Western countries continually debate the budgetary impact of expensive drugs, but unaffordability in low income countries is rarely discussed, they note.

The cheap cost of labour means that these expensive drugs are rarely going to be considered a return on investment, in terms of improved productivity, they add, and drug pricing in Europe should be revised, say the authors.

Explore further: Almost one-quarter of European countries do not provide access to biologics for arthritis

More information: www.ard.bmj.com/lookup/doi/10. … rheumdis-2012-202603

Related Stories

Almost one-quarter of European countries do not provide access to biologics for arthritis

June 6, 2012
Data from a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates the vast inequalities in access to biologics for the treatments of rheumatoid arthritis (RA) across ...

ACR updates guidelines for use of DMARDs and biologic drugs in treating rheumatoid arthritis

April 2, 2012
The American College of Rheumatology (ACR) has released the 2012 recommendations for the use of disease-modifying antirheumatic drugs (DMARDs) and biologic agents in the treatment of rheumatoid arthritis (RA). The guidelines ...

Antirheumatic drugs have minor effect on preeclampsia risk

November 6, 2012
(HealthDay)—The use of a disease-modifying antirheumatic drug (DMARD) during pregnancy is rare and is associated with a nonsignificant increase in the risk for preeclampsia in women with autoimmune disease, according to ...

Recommended for you

More doctor visits lead to less suicide attempts for fibromyalgia patients

September 19, 2018
Fibromyalgia patients who regularly visit their physicians are much less likely to attempt suicide than those who do not, according to a new Vanderbilt University Medical Center study published in Arthritis Care & Research.

Antioxidant found to be effective in treating mice with osteoarthritis

September 14, 2018
A team of researchers in Belgium and the Netherlands has found that feeding a common antioxidant to test mice was effective in treating osteoarthritis. In their paper published in Science Translational Medicine, the group ...

Researchers find answers as to why some people are at risk of gout

September 12, 2018
University of Otago researchers have helped characterise a genetic variant that enables new understanding of why some people are at risk of gout, a painful and debilitating arthritic disease.

Emotions like anger and sadness may cause pain as well as being a result of it

September 10, 2018
While emotions such as anger or sadness are often thought of as being a result of stress or pain, findings recently published by Penn State researchers suggest that negative or mixed emotions could function as stressors themselves.

Dietary carbohydrates could lead to osteoarthritis, new study finds

August 9, 2018
Do your knees ache? According to new findings from the Oklahoma Medical Research Foundation, your diet could be a culprit.

Joint study raises questions about treatments for arthritis

August 3, 2018
A study examining how molecules are transported into knee-joint tissue could have major implications for understanding and treating arthritis.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.